40–80 mg/day of isoflavones.
⏱ 3 min read
Red clover is Trifolium pratense, a legume common in European and American meadows whose flowers and aerial parts have traditionally been used for multiple indications (blood purification, skin problems, chronic cough) in European pharmacopeias; in recent decades, standardized red clover extracts have become established as one of the main sources of isoflavones for the treatment of climacteric symptoms in postmenopausal women, alongside soy and Pueraria mirifica, with a specific isoflavone profile that differs slightly from that of soy and offers particular pharmacological characteristics.
Unlike soy (rich predominantly in genistein and daidzein), red clover provides significant amounts of formononetin and biochanin A in addition to daidzein and genistein; formononetin and biochanin A are metabolized in the intestine to daidzein and genistein respectively, and secondarily to their active metabolites (especially equol, produced by specific intestinal bacteria, with a significantly greater estrogenic affinity than the parent isoflavones); this metabolic characteristic positions red clover as an efficient source of isoflavones with clinically relevant estrogenic potential.
The most studied indication with clinical support is the relief of hot flashes and night sweats in postmenopausal women: several randomized trials and meta-analyses have documented modest but significant reductions in the frequency and intensity of hot flashes with supplementation at 40-80 milligrams daily of red clover isoflavones for 12-24 weeks, with magnitudes generally similar to those of soy isoflavones (modest) and significantly lower than those of hormone replacement therapy with pharmaceutical estrogens.
Effects vary between studies and between individuals, possibly because of genetic variability in the individual metabolism of isoflavones to equol (equol-producing women obtain greater benefits) and because of differences in the exact composition of the commercial extracts used; the most studied specific preparations (Promensil and similar) have shown more consistent results than generic products.
In postmenopausal osteoporosis, several studies have documented modest improvements in biochemical bone markers and slight reductions in bone mineral density loss with supplementation over months; the effects are quantitatively smaller than those of bisphosphonates or pharmaceutical estrogens, but may have a place as a complement.
On the lipid profile, red clover isoflavones have shown modest effects on HDL cholesterol and, to a lesser extent, on LDL in some studies, an indication consistent with the general effects of phytoestrogens on lipid metabolism.
The doses studied range from 40 to 80 milligrams daily of total isoflavones (typically expressed as aglycones), divided into one or two doses with or without food; typical commercial products contain 40 mg of isoflavones per capsule, such as Promensil and similar, with standardized concentration; the effect on climacteric symptoms appears gradually and requires at least 8-12 weeks for evaluation.
Generally well tolerated at the doses studied; the adverse effects described are rare and mild (mild digestive discomfort, occasionally headache); the safety considerations are similar to those of other phytoestrogens: people with active or recent breast, endometrial, ovarian, or other hormone-dependent cancers, or with a strong family history, should consult their oncologist before starting supplementation; those who take tamoxifen or aromatase inhibitors as adjuvant treatment for breast cancer face a complex situation with heterogeneous data on pharmacodynamic interaction; those who take hormone replacement therapy do not need additional red clover, and the combination may produce additive hormonal effects; people with a history of thromboembolism should use theoretical caution because of the estrogenic effect; those who take warfarin-type anticoagulants should use caution because of a possible mild potentiation of the anticoagulant effect from the natural coumarin content of red clover (a characteristic that distinguishes red clover from soy); in pregnancy it is contraindicated because of its hormonal activity; in breastfeeding the data are limited and it is discouraged as a precaution; nonstandardized products vary enormously in their content of active isoflavones, and it is advisable to choose products with a specific declaration of total isoflavone content or, ideally, of specific components (biochanin A, formononetin, daidzein, genistein).
Information, not medical advice. Scientific evidence reflects the quality of the studies.